<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">34163070</PMID><DateRevised><Year>2021</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>595</Volume><Issue>7868</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Clonal fitness inferred from time-series modelling of single-cell cancer genomes.</ArticleTitle><Pagination><MedlinePgn>585-590</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-021-03648-3</ELocationID><Abstract><AbstractText>Progress in defining genomic fitness landscapes in cancer, especially those defined by copy number alterations (CNAs), has been impeded by lack of time-series single-cell sampling of polyclonal populations and temporal statistical models<sup>1-7</sup>. Here we generated 42,000 genomes from multi-year time-series single-cell whole-genome sequencing of breast epithelium and primary triple-negative breast cancer (TNBC) patient-derived xenografts (PDXs), revealing the nature of CNA-defined clonal fitness dynamics induced by TP53 mutation and cisplatin chemotherapy. Using a new Wright-Fisher population genetics model<sup>8,9</sup> to infer clonal fitness, we found that TP53 mutation alters the fitness landscape, reproducibly distributing fitness over a larger number of clones associated with distinct CNAs. Furthermore, in TNBC PDX models with mutated TP53, inferred fitness coefficients from CNA-based genotypes accurately forecast experimentally enforced clonal competition dynamics. Drug treatment in three long-term serially passaged TNBC PDXs resulted in cisplatin-resistant clones emerging from low-fitness phylogenetic lineages in the untreated setting. Conversely, high-fitness clones from treatment-naive controls were eradicated, signalling an inversion of the fitness landscape. Finally, upon release of drug, selection pressure dynamics were reversed, indicating a fitness cost of treatment resistance. Together, our findings define clonal fitness linked to both CNA and therapeutic resistance in polyclonal tumours.</AbstractText><CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Salehi</LastName><ForeName>Sohrab</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kabeer</LastName><ForeName>Farhia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceglia</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andronescu</LastName><ForeName>Mirela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Marc J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-5524-4174</Identifier><AffiliationInfo><Affiliation>Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Kieran R</ForeName><Initials>KR</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1981-5763</Identifier><AffiliationInfo><Affiliation>Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital Joseph &amp; Wolf Lebovic Health Complex, Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masud</LastName><ForeName>Tehmina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Beixi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biele</LastName><ForeName>Justina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brimhall</LastName><ForeName>Jazmine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gee</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hakwoo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ting</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Allen W</ForeName><Initials>AW</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7606-089X</Identifier><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Hoa</ForeName><Initials>H</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-9547-8650</Identifier><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Flanagan</LastName><ForeName>Ciara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorri</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusk</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-2663-6288</Identifier><AffiliationInfo><Affiliation>Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Algara</LastName><ForeName>Teresa Ruiz</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>So Ra</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Brian Yu Chieh</ForeName><Initials>BYC</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-9258-8184</Identifier><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eirew</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kono</LastName><ForeName>Takako</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Jenifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grewal</LastName><ForeName>Diljot</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-9203-6323</Identifier><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mungall</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Marco A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-7146-7175</Identifier><AffiliationInfo><Affiliation>Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>IMAXT Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>McPherson</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouchard-Côté</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Statistics, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aparicio</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0487-9599</Identifier><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada. saparicio@bccrc.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. saparicio@bccrc.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Sohrab P</ForeName><Initials>SP</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-6402-523X</Identifier><AffiliationInfo><Affiliation>Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. shahs3@mskcc.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><InvestigatorList><Investigator ValidYN="Y"><LastName>Hannon</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Battistoni</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bressan</LastName><ForeName>Dario</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cannell</LastName><ForeName>Ian Gordon</ForeName><Initials>IG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casbolt</LastName><ForeName>Hannah</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fatemi</LastName><ForeName>Atefeh</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jauset</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kovačević</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulvey</LastName><ForeName>Claire M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nugent</LastName><ForeName>Fiona</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ribes</LastName><ForeName>Marta Paez</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearsall</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qosaj</LastName><ForeName>Fatime</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sawicka</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wild</LastName><ForeName>Sophia A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laks</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Yangguang</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Flanagan</LastName><ForeName>Ciara H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lai</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roth</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balasubramanian</LastName><ForeName>Shankar</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Maximillian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodenmiller</LastName><ForeName>Bernd</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burger</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuett</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tietscher</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Windhager</LastName><ForeName>Jonas</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyden</LastName><ForeName>Edward S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alon</LastName><ForeName>Shahar</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cui</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emenari</LastName><ForeName>Amauche</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karagiannis</LastName><ForeName>Emmanouil D</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinha</LastName><ForeName>Anubhav</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wassie</LastName><ForeName>Asmamaw T</ForeName><Initials>AT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldas</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruna</LastName><ForeName>Alejandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Callari</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenwood</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerda</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eyal-Lubling</LastName><ForeName>Yaniv</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rueda</LastName><ForeName>Oscar M</ForeName><Initials>OM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shea</LastName><ForeName>Abigail</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>Robby</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimaldi</LastName><ForeName>Flaminia</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Suvi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vogl</LastName><ForeName>Sara Lisa</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weselak</LastName><ForeName>Joanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joyce</LastName><ForeName>Johanna A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>Spencer S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vázquez-Garćıa</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tavaré</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dinh</LastName><ForeName>Khanh N</ForeName><Initials>KN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>Eyal</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunes</LastName><ForeName>Russell</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walton</LastName><ForeName>Nicholas A</ForeName><Initials>NA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sa'd</LastName><ForeName>Mohammad Al</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chornay</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dariush</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>González-Solares</LastName><ForeName>Eduardo A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>González-Fernández</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoldas</LastName><ForeName>Aybüke Küpcü</ForeName><Initials>AK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Millar</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitmarsh</LastName><ForeName>Tristan</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fan</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Hsuan</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sepúlveda</LastName><ForeName>Leonardo A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xia</LastName><ForeName>Chenglong</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zheng</LastName><ForeName>Pu</ForeName><Initials>P</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>05</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34163070</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03648-3</ArticleId><ArticleId IdType="pii">10.1038/s41586-021-03648-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32025013</ArticleId><ArticleId IdType="pmcid">7054212</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1907-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, M. J. et al. Quantification of subclonal selection in cancer from bulk sequencing data. Nat. Genet. 50, 895–903 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29808029</ArticleId><ArticleId IdType="pmcid">6475346</ArticleId><ArticleId IdType="doi">10.1038/s41588-018-0128-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Salichos, L., Meyerson, W., Warrell, J. &amp; Gerstein, M. Estimating growth patterns and driver effects in tumor evolution from individual samples. Nat. Commun. 11, 732 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32024824</ArticleId><ArticleId IdType="pmcid">7002450</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-14407-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395–399 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22495314</ArticleId><ArticleId IdType="doi">10.1038/nature10933</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. et al. Patterns of somatic structural variation in human cancer genomes. Nature 578, 112–121 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32025012</ArticleId><ArticleId IdType="pmcid">7025897</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1913-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27135926</ArticleId><ArticleId IdType="pmcid">27135926</ArticleId><ArticleId IdType="doi">10.1038/nature17676</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">3440846</ArticleId><ArticleId IdType="pmcid">3440846</ArticleId><ArticleId IdType="doi">10.1038/nature10983</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright, S. The distribution of gene frequencies in populations. Proc. Natl Acad. Sci. USA 23, 307–320 (1937).</Citation><ArticleIdList><ArticleId IdType="pubmed">16577780</ArticleId><ArticleId IdType="pmcid">1076930</ArticleId><ArticleId IdType="doi">10.1073/pnas.23.6.307</ArticleId></ArticleIdList></Reference><Reference><Citation>Tataru, P., Simonsen, M., Bataillon, T. &amp; Hobolth, A. Statistical inference in the Wright–Fisher model using allele frequency data. Syst. Biol. 66, e30–e46 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28173553</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasan, N., Baselga, J. &amp; Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299–309 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31723286</ArticleId><ArticleId IdType="pmcid">8008476</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1730-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-David, U. &amp; Amon, A. Context is everything: aneuploidy in cancer. Nat. Rev. Genet. 21, 44–62 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31548659</ArticleId><ArticleId IdType="doi">10.1038/s41576-019-0171-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunshine, A. B. et al. The fitness consequences of aneuploidy are driven by condition-dependent gene effects. PLoS Biol. 13, e1002155 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26011532</ArticleId><ArticleId IdType="pmcid">4444335</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.1002155</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheltzer, J. M., Torres, E. M., Dunham, M. J. &amp; Amon, A. Transcriptional consequences of aneuploidy. Proc. Natl Acad. Sci. USA 109, 12644–12649 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22802626</ArticleId><ArticleId IdType="pmcid">3411958</ArticleId><ArticleId IdType="doi">10.1073/pnas.1209227109</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A. &amp; Sottoriva, A. Identification of neutral tumor evolution across cancer types. Nat. Genet. 48, 238–244 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26780609</ArticleId><ArticleId IdType="pmcid">4934603</ArticleId><ArticleId IdType="doi">10.1038/ng.3489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22608083</ArticleId><ArticleId IdType="pmcid">3428864</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2012.04.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041.e21 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29056346</ArticleId><ArticleId IdType="pmcid">5720395</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2017.09.042</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, K. H. et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov. 8, 1270–1285 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30166348</ArticleId><ArticleId IdType="pmcid">6380469</ArticleId><ArticleId IdType="doi">10.1158/2159-8290.CD-17-0891</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24487277</ArticleId><ArticleId IdType="pmcid">4636053</ArticleId><ArticleId IdType="doi">10.1038/ng.2891</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamal-Hanjani, M. et al. Tracking the evolution of non–small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1616288</ArticleId></ArticleIdList></Reference><Reference><Citation>López, S. et al. Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nat. Genet. 52, 283–293 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32139907</ArticleId><ArticleId IdType="pmcid">7116784</ArticleId><ArticleId IdType="doi">10.1038/s41588-020-0584-7</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherson, A. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758–767 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27182968</ArticleId><ArticleId IdType="doi">10.1038/ng.3573</ArticleId></ArticleIdList></Reference><Reference><Citation>Good, B. H., McDonald, M. J., Barrick, J. E., Lenski, R. E. &amp; Desai, M. M. The dynamics of molecular evolution over 60,000 generations. Nature 551, 45–50 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29045390</ArticleId><ArticleId IdType="pmcid">5788700</ArticleId><ArticleId IdType="doi">10.1038/nature24287</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorri, F. et al. Efficient Bayesian inference of phylogenetic trees from large scale, low-depth genome-wide single-cell data. Preprint at https://doi.org/10.1101/2020.05.06.058180 (2020).</Citation></Reference><Reference><Citation>Burleigh, A. et al. A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. Breast Cancer Res. 17, 4 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25572802</ArticleId><ArticleId IdType="pmcid">4322558</ArticleId><ArticleId IdType="doi">10.1186/s13058-014-0510-y</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Vega, M. R., Chapman, E. &amp; Zhang, D. D. NRF2 and the Hallmarks of cancer. Cancer Cell 34, 21–43 (2018).</Citation><ArticleIdList><ArticleId IdType="pmcid">6039250</ArticleId><ArticleId IdType="doi">10.1016/j.ccell.2018.03.022</ArticleId><ArticleId IdType="pubmed">6039250</ArticleId></ArticleIdList></Reference><Reference><Citation>The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11412</ArticleId></ArticleIdList></Reference><Reference><Citation>Patch, A.-M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26017449</ArticleId><ArticleId IdType="pmcid">26017449</ArticleId><ArticleId IdType="doi">10.1038/nature14410</ArticleId></ArticleIdList></Reference><Reference><Citation>Laks, E. et al. Clonal decomposition and DNA replication states defined by scaled single-cell genome sequencing. Cell 179, 1207–1221 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31730858</ArticleId><ArticleId IdType="pmcid">6912164</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.10.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Hather, G. et al. Growth rate analysis and efficient experimental design for tumor xenograft studies. Cancer Inform. 13, 65–72 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25574127</ArticleId><ArticleId IdType="pmcid">4264612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30013179</ArticleId><ArticleId IdType="pmcid">6072608</ArticleId><ArticleId IdType="doi">10.1038/s41588-018-0165-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakhoum, S. F. et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553, 467–472 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29342134</ArticleId><ArticleId IdType="pmcid">5785464</ArticleId><ArticleId IdType="doi">10.1038/nature25432</ArticleId></ArticleIdList></Reference><Reference><Citation>Davoli, T., Uno, H., Wooten, E. C. &amp; Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28104840</ArticleId><ArticleId IdType="pmcid">5592794</ArticleId><ArticleId IdType="doi">10.1126/science.aaf8399</ArticleId></ArticleIdList></Reference><Reference><Citation>Acar, A. et al. Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nat. Commun. 11, 1923 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32317663</ArticleId><ArticleId IdType="pmcid">7174377</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-15596-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422–426 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25470049</ArticleId><ArticleId IdType="doi">10.1038/nature13952</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, D. et al. Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer. Cancer Gene Ther. 20, 251–259 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23470565</ArticleId><ArticleId IdType="doi">10.1038/cgt.2013.14</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway. PLoS ONE 8, e57391 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23437382</ArticleId><ArticleId IdType="pmcid">3578855</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0057391</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Flanagan, C. H. et al. Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses. Genome Biol. 20, 210 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">6796327</ArticleId><ArticleId IdType="pmcid">6796327</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24633410</ArticleId><ArticleId IdType="pmcid">4864026</ArticleId><ArticleId IdType="doi">10.1038/nmeth.2883</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaumont, M. A., Cornuet, J.-M., Marin, J.-M. &amp; Robert, C. P. Adaptive approximate Bayesian computation. Biometrika 96, 983–990 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/asp052</ArticleId></ArticleIdList></Reference><Reference><Citation>Foll, M. et al. Influenza virus drug resistance: a time-sampled population genetics perspective. PLoS Genet. 10, e1004185 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24586206</ArticleId><ArticleId IdType="pmcid">3937227</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1004185</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollback, J. P., York, T. L. &amp; Nielsen, R. Estimation of 2Nes from temporal allele frequency data. Genetics 179, 497–502 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18493066</ArticleId><ArticleId IdType="pmcid">2390626</ArticleId><ArticleId IdType="doi">10.1534/genetics.107.085019</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspinas, A.-S., Malaspinas, O., Evans, S. N. &amp; Slatkin, M. Estimating allele age and selection coefficient from time-serial data. Genetics 192, 599–607 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22851647</ArticleId><ArticleId IdType="pmcid">3454883</ArticleId><ArticleId IdType="doi">10.1534/genetics.112.140939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer-Admetlla, A., Leuenberger, C., Jensen, J. D. &amp; Wegmann, D. An approximate Markov model for the Wright–Fisher diffusion and its application to time series data. Genetics 203, 831–846 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27038112</ArticleId><ArticleId IdType="pmcid">4896197</ArticleId><ArticleId IdType="doi">10.1534/genetics.115.184598</ArticleId></ArticleIdList></Reference><Reference><Citation>Beskos, A. et al. Exact simulation of diffusions. Ann. Appl. Probab. 15, 2422–2444 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/105051605000000485</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock, M. et al. On the exact and ε-strong simulation of (jump) diffusions. Bernoulli 22, 794–856 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.3150/14-BEJ676</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins, P. A. et al. Exact simulation of the Wright–Fisher diffusion. Ann. Appl. Probab. 27, 1478–1509 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/16-AAP1236</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchet, J. Exact simulation for multivariate Itô diffusions. Adv. Appl. Probab. 52, 1003-1 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/apr.2020.39</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorde, P., Palm, S. &amp; Ryman, N. Estimating genetic drift and effective population size from temporal shifts in dominant gene marker frequencies. Mol. Ecol. 8, 1171–1178 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-294x.1999.00676.x</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>